Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

US Department of Health and Human Services

- PMLiVE

Ten participating drugmakers invited for further US Medicare drug price negotiations

ASPE revealed that the IRA is expected to save around 857,000 US women $1,000 or more in 2025

- PMLiVE

Drugmakers submit counteroffers to US Medicare pricing negotiations

New negotiated prices are set to be announced by 1 September 2024 and implemented in 2026

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Top 10 HEOR trends – A detailed look at ISPOR’s 2024–2025 topics

Specialists from across Mtech Access to look at each of ISPOR’s top 10 HEOR trends for 2024–2025. Jump in as the Mtech Access experts give their hot take on each...

Mtech Access

- PMLiVE

US government announces first ten drugs subject to Medicare pricing negotiations

The IRA programme is facing court challenges from leading drugmakers and industry groups

- PMLiVE

AstraZeneca latest to sue US government over Medicare drug price negotiation plan

The programme already faces court challenges from drugmakers and industry groups

- PMLiVE

Boehringer sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for selected medicines

- PMLiVE

Johnson & Johnson sues US government over Medicare drug price negotiation programme

The IRA allows Medicare to negotiate lower prices for a selected group of medicines

- PMLiVE

Merck sues US government over Medicare drug price negotiation programme

The drugmaker says the programme violates the First and Fifth Amendments to the US Constitution

- PMLiVE

The challenges of reimbursement and innovative pricing for cell and gene therapies

Our policy and market access experts at Avalere, part of Fishawack Health, share insights on the reimbursement challenges for cell and gene therapies and discuss the challenges and opportunities of...

Avalere Health

- PMLiVE

US government announces first set of drugs subject to Medicare inflation rebates

The move could reduce out-of-pocket costs for Medicare beneficiaries by up to $390 per dose

- PMLiVE

US health department proposes three new models to help lower cost of drugs

One suggested model includes offering some essential generic drugs for $2 a month

- PMLiVE

Pfizer announces commitment to achieve Net-Zero Standard by 2040

The company hopes to achieve the net-zero target ten years earlier than the expectations of the Net-Zero Standard

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links